ATHE

Alterity Therapeutics Limited

Healthcare · $62M market cap

We can't put a fair value on ATHE right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?

Equity per share growth-9.6% a year✗

Sales growth12.5% a year✓

Free cash flow growth—?

Return on invested capital-47.1%✗

Follow ATHE

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Aug 31, 2026: 2 open-market purchases worth $48K. Why purchases matter

Purchases

Stamler David Allen

Chief Executive Officer · 2026-08-31

Bought

$24K

Marks Peter Ashley

director · 2026-08-31

Bought

$24K

About Alterity Therapeutics Limited

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works

Verdict

Business quality

Insider activity

Purchases

About Alterity Therapeutics Limited